卡培他滨维持化疗治疗晚期胃癌和术后复发转移胃癌的安全性及预后分析

摘要

Objective:To study the effect of capecitabine on advanced gastric cancer postoperative recurrence and metastasis.Methods:To retrospectively analyze clinical data of 120 patients with gastric cancer.Patients were divided into groups of docetaxel,oxaliplatin group,control group,40 cases in each group.Oxaliplatin group was treated with oxaliplatin,capecitabine combined with docetaxel to docetaxel treatment,group,card capecitabine combination thera-py,the control group received capecitabine treatment alone.Results:In oxaliplatin group RR was 80.0%,and do-cetaxel group (70.0%),compared with the control group(50.0%),showed a significant difference (P <0.05).Ox-aliplatin group DCR(90.0%),compared with docetaxel (85.0%),with no difference (P >0.05),and control group (65.0%)(P <0.05).Docetaxel,oxaliplatin group after treatment the serum CEA,CA50,CA199,CA125 and control group were compared,there were significant differences (P <0.05),but the oxaliplatin group and docetaxel groups compared,had no difference (P >0.05 ).Docetaxel,oxaliplatin group after treatment group and the control group compared with the quality of life score,showed significant difference (P <0.05 ),oxaliplatin and docetaxel group compared with the group,showed significant difference (P <0.05).The occurrence of the adverse reaction rate in three groups,with no difference (P >0.05).Conclusion:advanced gastric cancer,postoperative recurrence and me-tastasis in patients with gastric cancer application of oxaliplatin,capecitabine combined treatment,can improve the treatment efficiency and disease control rate,and can improve the prognosis of serum CEA,CA50,optimization, CA199,CA125 levels,and has no adverse reaction.%目的：研究晚期胃癌、术后复发转移胃癌患者应用卡培他滨不同方案治疗的临床效果。方法：回顾分析我院自2010年8月至2013年8月以来，于我科治疗的120例胃癌患者临床资料，依据治疗方案将其分为奥沙利铂组、多西紫杉醇组、对照组，每组40例，奥沙利铂组予以奥沙利铂、卡培他滨联合治疗，多西紫杉醇组予以多西紫杉醇、卡培他滨联合治疗，对照组予以卡培他滨单独治疗，观察对比治疗14d 后三组的临床疗效、DCR（疾病控制率），三组血清 CEA、CA50、CA199、CA125改变情况，三组生存质量及不良反应等情况。结果：奥沙利铂组 RR 为80．0％，与多西紫杉醇组（70．0％）、对照组（50．0％）相较，均呈明显差异（P ＜0．05）。奥沙利铂组 DCR 为90．0％，与多西紫杉醇组（85．0％）相较，无统计学差异（P ＞0．05），与对照组（65．0％）相较，呈明显差异（P ＜0．05）。奥沙利铂组、多西紫杉醇组治疗后血清 CEA、CA50、CA199、CA125与对照组相较，均存在明显差异（P ＜0．05），但奥沙利铂组与多西紫杉醇组相较，无统计学差异（P ＞0．05）。奥沙利铂组、多西紫杉醇组治疗后生活质量评分与对照组相较，呈明显差异（P ＜0．05），奥沙利铂组与多西紫杉醇组相较，呈明显差异（P ＜0．05）。三组各项不良反应发生率相较，无统计学差异（P ＞0．05）。结论：晚期胃癌、术后复发转移胃癌患者应用奥沙利铂、卡培他滨联合治疗，可以提高治疗的有效率和疾病控制率，而且可以改善预后生存质量，优化血清 CEA、CA50、CA 199、CA 125水平，无额外的不良反应，安全稳定，效果显著，应予推广。